載入中
NYSEHealthcareMedical - Care Facilities
最新資料
US$21.06
+US$0.18 · +0.86%
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
前收盤價
US$21.06
+US$0.18 · +0.86%
盤中時間採用ET。市場資料可能有所延遲。
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
日內區間
目前US$21.06
52週區間
目前US$21.06
盤中時間採用ET。市場資料可能有所延遲。
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
日內區間
目前US$21.06
52週區間
目前US$21.06
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 196.28億 EUR | 193.36億 EUR | 194.54億 EUR | 193.98億 EUR | 176.19億 EUR |
| 銷貨成本 | 145.99億 EUR | 145.79億 EUR | 145.29億 EUR | 145.04億 EUR | 128.46億 EUR |
| 毛利 | 50.29億 EUR | 47.57億 EUR | 49.25億 EUR | 48.94億 EUR | 47.73億 EUR |
| 研究與開發 | 1.58億 EUR | 1.83億 EUR | 2.32億 EUR | 2.29億 EUR | 2.21億 EUR |
| 銷售、一般及管理費用 | 30.33億 EUR | 31.43億 EUR | 31.96億 EUR | 31.7億 EUR | 27.73億 EUR |
| 營業費用 | 32.02億 EUR | 32.89億 EUR | 35.56億 EUR | 33.82億 EUR | 29.21億 EUR |
| 利息收入 | 6961.1萬 EUR | 7157.5萬 EUR | 8821.7萬 EUR | 6766.3萬 EUR | 7317萬 EUR |
| 利息支出 | 3.84億 EUR | 4.07億 EUR | 4.25億 EUR | 3.6億 EUR | 3.54億 EUR |
| 折舊和攤銷 | 15億 EUR | 17.42億 EUR | 17.52億 EUR | 18.38億 EUR | 16.24億 EUR |
| 營業利益 | 18.27億 EUR | 14.67億 EUR | 13.69億 EUR | 15.12億 EUR | 18.52億 EUR |
| 淨利 | 9.78億 EUR | 5.38億 EUR | 4.99億 EUR | 6.73億 EUR | 9.69億 EUR |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Pzena U.S. Large Cap Value ETFPZLV223.64萬3.20%6900萬 USD0.60%US$30.1890.00%
Avantis International Equity ETFAVDE118.59萬0.01%192.24億 USD0.23%US$89.80+0.58%
iShares Flexible Equity Active ETFBFLX109.32萬0.05%21.89億 USD0.40%US$26.1102+0.67%
ActivePassive International Equity ETFAPIE65.64萬0.06%11.41億 USD0.45%US$38.56+0.65%
ETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIV36.15萬1.13%3209.03萬 USD0.54%US$29.86+0.50%
ETF Opportunities Trust - Cultivar ETFCVAR28.07萬0.63%4474.66萬 USD0.87%US$30.32770.00%
Dimensional - International Core Equity Market ETFDFAI7.34萬0.00%177.82億 USD0.18%US$41.34+0.66%
Dimensional - International Value ETFDFIV3.09萬0.00%213.87億 USD0.27%US$55.42+0.25%Pzena U.S. Large Cap Value ETFPZLVAvantis International Equity ETFAVDEiShares Flexible Equity Active ETFBFLXActivePassive International Equity ETFAPIEETF Series Solutions - AAM Todd International Intrinsic Value ETFTIIVETF Opportunities Trust - Cultivar ETFCVARDimensional - International Core Equity Market ETFDFAIDimensional - International Value ETFDFIVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
